

Press Release

Thursday, May 26, 2016

Strides Shasun Limited Strides House, Bannerghatta Road, Bangalore – 560076.

Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet

Product approval from Oral dosage facility at Bangalore

Bangalore, May 26, 2016 Strides Shasun Limited today announced that it has received tentative approval from the United States Food & Drug Administration (USFDA) for **Efavirenz Tablet USP, 600 mg.**

The final approval will be received after Patent Expiry in August 2018.

According to IMS data, the US market for Efavirenz 600 mg Tablet is approximately USD 150 Million. The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides in the US Market.

About Efavirenz

Efavirenz Tablet is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents.

About Strides Shasun Limited

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 14 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

Strides Shasun

Badree Komandur, Group CFO +91 80 6784 0747

Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com

K Priya: +91 9535425418 priya@fortunapr.com